Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Single arm, single site, open-label Phase II study of the effects of oral olaparib in
participants with metastatic renal cell carcinoma that harbor an inactivating mutation in
BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,
RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint
inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1
criteria.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins